Well-Managed Formularies Control Drug Costs
A strategic formulary, used alongside rigorous utilization management and thoughtful benefit design, plays a pivotal role in controlling pharmaceutical trends. The annual waste on low-value medications that fail to improve health outcomes for State correctional patients is estimated to be around $16 billion. This waste is a significant part of the broader issue of healthcare inefficiencies, which also includes administrative costs, operational inefficiencies, and low-value care overall.
(ProPublica) (The Peter G. Peterson Foundation)
We Support Clinically-Driven Formulary Management
- Clinical Appropriateness Over Cost
- Ensuring patients have access to the most appropriate therapies for their conditions takes precedence over potential savings or rebates.
- Comprehensive Coverage
- Formularies should cover a wide range of conditions and include a process for exceptions to accommodate non-preferred drugs when clinically necessary.
- Independent Evaluations
- Formulary decisions are based on assessments from independent physicians, ensuring that clinical efficacy is the primary consideration.
4PillarsRx remains informed about the latest drug developments, tracking drugs in early clinical trials to proactively design formularies and programs in anticipation of new approvals. This proactive approach ensures that formularies are continually updated to reflect the best clinical practices.
Effectively managing drug formularies is crucial in addressing this issue and reducing the substantial financial burden caused by unnecessary medication expenditures
An optimal formulary balances access to clinically effective medications with plan-specific needs. Some plans prioritize broad options for members, while others exclude high-cost drugs with limited added benefit.
Without effective formulary management, plan sponsors risk much higher drug costs. Escalating prescription drug prices remain a major issue for states, especially in correctional systems. Recent data on per-patient annual costs for non-specialty medications in state prisons is sparse, but estimates around $1,200 (from earlier 2023 reports) persist amid ongoing challenges; some local jail systems report sharp rises in total pharmacy spending (e.g., 30–50% increases since 2019 nationally, driven by mental health and specialty needs). Specialty drugs remain far more expensive—often tens of thousands per patient annually—due to their complexity and targeted conditions (Managed Healthcare Executive; Pharmacy Times; recent correctional health analyses).
Drug prices once rose faster than inflation, but trends have moderated. Between July 2021 and July 2022, over 1,200 drugs saw average list price hikes of 31.6%, outpacing 8.5% inflation (ASPE; AARP). Recent years show slower growth: brand-name list increases averaged around 15% in some 2022–2023 periods, dropping to 2–3.5% annually by 2024–2025 in certain reports, with net prices (after rebates) sometimes declining due to policies like the Inflation Reduction Act and market dynamics (ASPE; AARP; industry trends). Overall U.S. prescription spending grew ~10% in 2024, fueled more by utilization, new high-cost therapies (e.g., for obesity, oncology, immunology), and fewer pure price-driven rises.
Without effective formulary management, plan sponsors risk much higher drug costs. Escalating prescription drug prices remain a major issue for states, especially in correctional systems. Recent data on per-patient annual costs for non-specialty medications in state prisons is sparse, but estimates around $1,200 (from earlier 2023 reports) persist amid ongoing challenges; some local jail systems report sharp rises in total pharmacy spending (e.g., 30–50% increases since 2019 nationally, driven by mental health and specialty needs). Specialty drugs remain far more expensive—often tens of thousands per patient annually—due to their complexity and targeted conditions (Managed Healthcare Executive; Pharmacy Times; recent correctional health analyses).
Drug prices once rose faster than inflation, but trends have moderated. Between July 2021 and July 2022, over 1,200 drugs saw average list price hikes of 31.6%, outpacing 8.5% inflation (ASPE; AARP). Recent years show slower growth: brand-name list increases averaged around 15% in some 2022–2023 periods, dropping to 2–3.5% annually by 2024–2025 in certain reports, with net prices (after rebates) sometimes declining due to policies like the Inflation Reduction Act and market dynamics (ASPE; AARP; industry trends). Overall U.S. prescription spending grew ~10% in 2024, fueled more by utilization, new high-cost therapies (e.g., for obesity, oncology, immunology), and fewer pure price-driven rises.
